PMC9926943_01
Pre-operative axial CT section at upper abdomen showing an enhancing mass in the tail of the pancreas
cureus-0015-00000033788-i01.jpg
PMC9926943_01_cureus-0015-00000033788-i01.jpg
FIG1
His further workup included a computed tomography scan of the abdomen (Figure 1) followed by endoscopic ultrasound-guided FNAB (fine needle aspiration biopsy) of pancreatic masses, which led to a clinical diagnosis of neuroendocrine tumor.
Ga-68 DOTA PET/CT pre-operative image showing pancreatic mass with increased uptake. DOTA - dodecane tetraacetic acid, PET - positron emission tomography
cureus-0015-00000033788-i02.jpg
PMC9926943_01_cureus-0015-00000033788-i02.jpg
FIG2
Given the aforementioned biochemical investigations and imaging, Ga-68 dodecane tetraacetic acid (DOTA) positron emission tomography (PET)/CT was performed to rule out any other foci (Figure 2), which was diagnostic of a neuroendocrine tumor.
Axial CT showing post-operative changes with visible surgical staples
cureus-0015-00000033788-i03.jpg
PMC9926943_01_cureus-0015-00000033788-i03.jpg
FIG3
The patient was followed up in the clinic after three months with both biochemical investigations and imaging (Figures 3, 4), neither of which showed any evidence of recurrence.
CT chest/abdomen coronal image showing post-operative changes with no evidence of recurrence
cureus-0015-00000033788-i04.jpg
PMC9926943_01_cureus-0015-00000033788-i04.jpg
FIG4
The patient was followed up in the clinic after three months with both biochemical investigations and imaging (Figures 3, 4), neither of which showed any evidence of recurrence.